rTMS for the Prevention Treatment of CM: a Single Arm Study

Chronic Migraine Clinical Trial

Official title:

Repetitive Transcranial Magnetic Stimulation for the Prevention Treatment of Chronic Migraine: a Single Arm Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03568617
• Other study ID #: rTMSCM-PUMCH
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 30, 2018
• Est. completion date: June 30, 2022

Study information

• Verified date: June 2018
• Source: gwcmc
• Contact: Yuzhou Guan, MD
• Phone: 8613910081750
• Email: guanyz001[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

We design this pilot, single arm study to explore the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) for the treatment of chronic migraine. The hypothetical control group is pooled sham group in latest meta-analysis. We expect a significant improvement of the outcome measures during and after the treatment as compared to the hypothetical control group.

Description:

After a 28-day prospective baseline period using a headache diary to record headache symptoms and any abortive medications used, subjects who meet diagnostic criteria for chronic migraine and don't meet the exclusion criteria will receive rTMS for 4 weeks. The outcome measure will be evaluated at 4 weeks. During the whole trial period, any adverse events are requested to be recorded in the headache diary for analyses. The primary outcome is 50% reduction in the number of days with headache. 50% reduction as assessed by migraine days, moderate/severe headache days, the mean VRS, and conversion to episodic migraine, SGIC, the change from baseline HALT-28, HIT-6, and MSQ v2.1, are used as secondary outcome measures for exploring other benefits associated with treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 15
• Est. completion date: June 30, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subjects meeting the diagnostic criteria for chronic migraine according to the International Classification of Headache Disorders, 3rd edition.

• The duration of chronic migraine = 6 months.

• age range of 18 - 65 years old

Exclusion Criteria:

• Secondary headaches except MOH

• any change of the prophylaxis or the analgesic drug strategy during the baseline and follow-up period

• structural brain lesions

• seizures

• severe systemic disease

• TMS contraindications (such as metal implants)

• psychosis

• severe depression or anxiety

• drug or alcohol dependence

• pregnancy

• participating in other experiments at the same time

Related Conditions & MeSH terms

• Chronic Migraine
• Migraine Disorders

Intervention

Device:
• rTMS
The subjects will receive 20 trains of 100 stimuli each delivered at 10 Hz and 80% of MT over the left MC (M1), 3 days a week, for 4 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
gwcmc

References & Publications (4)

Lan L, Zhang X, Li X, Rong X, Peng Y. The efficacy of transcranial magnetic stimulation on migraine: a meta-analysis of randomized controlled trails. J Headache Pain. 2017 Aug 22;18(1):86. doi: 10.1186/s10194-017-0792-4. Review. — View Citation

Shehata HS, Esmail EH, Abdelalim A, El-Jaafary S, Elmazny A, Sabbah A, Shalaby NM. Repetitive transcranial magnetic stimulation versus botulinum toxin injection in chronic migraine prophylaxis: a pilot randomized trial. J Pain Res. 2016 Oct 7;9:771-777. eCollection 2016. — View Citation

Steiner TJ, Lipton RB; Lifting The Burden: The Global Campaign against Headache. The Headache-Attributed Lost Time (HALT) Indices: measures of burden for clinical management and population-based research. J Headache Pain. 2018 Feb 2;19(1):12. doi: 10.1186/s10194-018-0837-3. — View Citation

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	50% reduction in the Number of Days with Headache	A Headache day is defined as a day with a headache that lasts at least 4 hours.	at 4 weeks
Secondary	50% reduction in the Number of Migraine Days	A migraine day is defined as a day with a headache that lasts at least 4 hours; meets ICHD-III criteria C and D for migraine without aura (1.1), B and C for migraine with aura (1.2), or ICHD-III criteria for probable migraine (1.6); or a day with a headache that is successfully treated with a triptan, ergotamine, or other migraine-specific acute medication.	at 4 weeks
Secondary	50% reduction in the Number of Moderate/Severe Headache Days	A moderate/severe headache day is defined as a day with moderate or severe pain that lasts at least 4 hours or a day with a headache that is successfully treated by an acute headache medication.	at 4 weeks
Secondary	Conversion to episodic migraine	Defined as the proportion of subjects with fewer than 14 migraine or headache days per 4 weeks.	at 4 weeks
Secondary	The Subject's Global Impression of Change (SGIC)	Global impression of change was scored using a 7-point scale for each instrument, ranging from 1 (very much improved) to 7 (very much worse), with a 4-week recall period. We'll estimate the proportion of patients who reported any improved (very much improved, much improved, minimally improved).	at 4 weeks
Secondary	Change from Baseline HALT-28 (Headache-Attributed Lost Time - 28 days)	HALT-30 is closely based on the first five questions of MIDAS, developed by RB Lipton and WF Stewart. We modify the time interval to capture migraine-related disability with a 4-week recall period.	at baseline and 4 weeks
Secondary	Change from Baseline HIT-6 (Headache Impact Test-6)	HIT-6 is for capturing migraine-related disability with a 4-week recall period.	at baseline and 4 weeks
Secondary	Change from Baseline MSQ v2.1 (the Migraine-Specific Quality of Life questionnaire v2.1)	To evaluate the change in quality of life related to chronic migraine with a 4-week recall period.	at baseline and 4 weeks
Secondary	50% reduction as assessed by the mean VRS	Subjects will be instructed to record the pain intensity of each day using 11-point Visual Rating Scale (VRS). The mean VRS is defined as the mean of the maximum VRS of each day with a 4-week period.	at 4 weeks